



Supernus Pharmaceuticals, Inc.  
Investor Relations Department  
1550 East Gude Drive  
Rockville, MD 20850  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: SUPN**

Last Trade:	41.85
Trade Time:	4:00 PM ET Jun 27, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	17.25 - 44.95
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

*Jun 21, 2017*

[Supernus Announces that its Partner Shire Receives FDA Approval for Mydavis™ for ADHD](#)

*Jun 1, 2017*

[Supernus to Present at Jefferies Healthcare Conference](#)

*May 9, 2017*

[Supernus Announces First Quarter 2017 Financial Results](#)

*Apr 26, 2017*

[Supernus to Host First Quarter 2017 Earnings Conference Call](#)

*Apr 5, 2017*

[Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents](#)

## Financials & Filings [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 16, 2017*

[Annual Report \(10-K\)](#)

*Apr 27, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Jan 20, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 5, 2016*

[Quarterly Report \(10-Q\)](#)